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Background
Malignant glioma is the most common primary brain tumor. 
The prevalence of all primary brain tumors is 130.8 per 100,000 
people, with approximately 350,000 individuals estimated to be 
living with this diagnosis in the United States every year.1 The 
current treatment strategies for malignant glioma include surgi-
cal resection followed by radiotherapy alone or in combination 
with chemotherapy. Despite this multimodal therapy, the median 
survival time is generally less than one year, and most patients 
die within two years.2 Glioblastoma multiforme (GBM) is an 
aggressive form of glioma that responds poorly to chemotherapy 
and is generally incurable. Cisplatin (DDP) is one of the most 
commonly used chemotherapeutic agents for glioma patients. 
However, the clinical response to cisplatin is not satisfactory due 
to a common drug resistance in gliomas.
In the present study, a high-resolution array comparative 
genomic hybridization (aCGH) was used to interrogate glioma 
genomes in a cisplatin-induced resistant cell line, U251/CP2, 
and its parental cell line, U251, to delineate any regions of 
genetic aberration. This study will provide important clues to 
identify genes associated with cisplatin resistance in this type 
of cancer.
Cisplatin is one of the most commonly used chemotherapeutic agents for glioma patients. In this study, array comparative 
genomic hybridization (aCGH) was used to identify genes associated with cisplatin resistance in a human glioma cell line. 
The cisplatin-resistant U251/CP2 cell line was derived by stepwise selection using cisplatin. The genetic aberrations of 
the U251 parental cell line and the U251/CP2 cells were analyzed using aCGH. RT-PCR was used to detect the expression 
of the altered genes revealed by aCGH. The sensitivity of glioma cells to cisplatin was determined by using the MTT 
assay. Apoptosis was detected using flow cytometry and western blot analysis. The IC50 value of cisplatin in U251/CP2 
cells was five times higher than its IC50 in U251 cells. The U251 cells lost at least one copy each of the CFHR1 and CFHR3 
genes, and both CFHR1 and CFHR3 were homozygously deleted in U251/CP2 cells. The U251/CP2 cells gained two to three 
copies of C8orf70 and IL-7 genes. IL-7 mRNA expression was studied in 12 glioma cell lines, and expression was positively 
correlated with the IC50 of cisplatin. Furthermore, IL-7 mRNA expression was also positively correlated with the IC50 of 
cisplatin in 91 clinical glioma specimens. Additionally, treatment with recombinant human IL-7 (rhIL-7) enhanced cisplatin 
resistance and increased the relative growth rate of the glioma cells. Moreover, the apoptosis induced by cisplatin could 
be inhibited by IL-7. In conclusion, our results suggest that IL-7 may play an important role in cisplatin resistance in glioma.
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Results
Selection of the U251/CP2 resistant line. To evaluate cisplatin-
sensitivity in glioma cells, 12 glioma lines were treated with vari-
ous concentrations of cisplatin and assayed for viability using the 
MTT assay. The IC50s of the 12 cell lines were listed in Table 3. 
The U251 cell line was sensitive to cisplatin treatment (IC50 was 
1.12 ± 0.12 μg/ml) and thus was chosen to create a cisplatin-
resistant subline. The U251/CP2 cisplatin-resistant cell subline 
was established by repeated exposure of the parental U251 cell 
line to escalating doses of cisplatin. After 10 mo of treatment, the 
cisplatin-resistant subline was cloned from the treated cultures. 
The IC50 for cisplatin in U251/CP2 cells was 5.43 ± 0.49 μg/ml. 
Compared with their parental line, the subline was more than 
5-fold resistant to cisplatin. Furthermore, the morphology of the 
U251 cells changed in response to cisplatin stimuli. The major-
ity of the U251 cells were long spindles and polygons, while the 
majority of the U251/CP2 cells became round and short spindles 
(Fig. 1A).
Array comparative genomic hybridization analysis. A series 
of normal vs. normal hybridizations was performed to define the 
normal variations of the test to reference the intensity ratio (Cy3/
Cy5) for each target clone. The hybridizations were normalized © 2012 Landes Bioscience.
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between -2.67 and -4.11 indicating that the entire CFHR1 and 
CFHR3 genes were homozygously deleted (Fig. 1B). The probes 
covering Chromosome 8 open reading frame 70 (C8orf70) and 
IL-7 exhibited increased copy numbers with log2 ratios in the 
range of ~1.6 (compared with -0.1 to -0.9 in U251 cells), sug-
gesting a gain of 2–3 copies of both genes in U251/CP2 cells 
(Fig. 1B). The aCGH results suggested that the loss of CFHR1 
and CFHR3, and the gain of C8orf70 and IL-7, might be related 
to the cisplatin resistance in U251/CP2 cells.
aCGH results confirmed by RT-PCR and FISH. To con-
firm the results of aCGH, the expression of CFHR1, CFHR3, 
C8orf70 and IL-7 mRNA was determined by RT-PCR in 
U251 and U251/CP2 cells. As shown in Figure 1C, CFHR1 
and CFHR3 transcripts were not detected in the parental and 
so that the overall ratio of green to red signals was centered 
at 1. With reference to previous aCGH studies, thresholds for 
copy number gain and loss were log2, ratio 0.2 and -0.2, respec-
tively. The aCGH results for the U251 and U251/CP2 cells, 
and representative aCGH profiles are illustrated in Figure 1B. 
In the U251 cells, probe P15399174 detected the expression of 
Complement factor H-related 3 (CFHR3) with a log2 ratio of 
-3.14, indicating an approximate loss of 90% of the target signals. 
Probe P35416170 detected the expression of Complement factor 
H-related 1 (CFHR1) with a log2 value of -2.41, which suggests 
an 80% loss of signal intensity. This suggested that the U251 
cells may have lost at least one copy each of CFHR1 and CFHR3 
(Fig. 1B). In U251/CP2 cells, there were four probes covering 
the CFHR3-CFHR1 region. All of the probes showed log2 ratios 
Figure 1. The screen of IL-7 about cisplatin resistance in glioma cells. (A) The morphological change of U251 cells in response to cisplatin stimuli. The 
majority of U251 cells were shaped like long spindles and polygons. The majority of U251/CP2 cells became round and short spindles. (B) Illustration 
of the chromosomal imbalances detected in the U251 and U251/CP2 cell lines by aCGH and RT-PCR confirmation. CFHR1 and CFHR3 were deleted in 
chromosome 1 in the U251 and U251/CP2 cell lines. C8orf70 and IL-7 were amplified in chromosome 8 in the U251 and U251/CP2 cells. The rectangles 
on the left and right side of ideogram indicate chromosomal losses and gains, respectively. (C) The result of aCGH was confirmed by RT-PCR. (D) The 
amplification of IL-7 U251/CP2 cells was identified using FISH. There was one copy of IL-7 in U251 cell, and the copy of IL-7 amplified in U251/CP2 cells.© 2012 Landes Bioscience.
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concentrations of cisplatin to evalu-
ate the effect of rhIL-7 on cispla-
tin resistance in glioma cells. Both 
10 ng/ml and 40 ng/ml of rhIL-7 
increased the IC50 for cisplatin in 
the cell lines with lower IL-7 expres-
sion, U251 and SKMG-1 (Table 4 
and Fig. 3D and E), while the IC50 
for cisplatin in cell lines with higher 
IL-7 expression, U251/CP2 and 
T98G, was reduced significantly 
following IL-7 RNA interference 
(Table 4 and Fig. 3F and G).
IL-7 promoted the growth of gli-
oma cells. Previous studies showed 
that IL-7 could promote the growth 
of breast cancer and leukemia cells.8,9 
Therefore, we further assessed the effect of IL-7 on cancer cell 
proliferation. After the addition of rhIL-7 at a concentration of 
40 ng/ml for 72 h, the relative growth rate of U251 and SKMG-1 
cells was increased to 1.40- and 1.32-fold, respectively, compared 
with the rate without rhIL-7. After IL-7 RNA interference, the 
relative growth rate of U251/CP2 and T98G cells decreased to 
0.74- and 0.81-fold, respectively, compared with the rate without 
IL-7 interference (Fig. 4).
IL-7 inhibited the apoptosis induced by cisplatin in glioma 
cells. Previous studies showed that IL-7 could inhibit apoptosis,10 
so we studied the effect of IL-7 on the apoptosis induced by cispl-
atin in glioma cells. By adding 40 ng/ml of rhIL-7, the apoptosis 
rate induced by cisplatin in SKMG-1 and U251 cells was reduced 
from 35.0 and 30.2% to 19.1 and 17.3%, respectively. Subsequent 
to IL-7 RNA interference, the cisplatin-induced apoptosis rate 
in U251/CP2 and T98G cells increased from 15.5 and 19.8% 
to 23.8 and 25.4%, respectively (Fig. 5A and B). Cleaved cas-
pase-3, an apoptosis related protein, was also detected by western 
blotting. Cleaved caspase-3 was reduced in U251 and SKMG-1 
cells that were stimulated by exogenous IL-7, and increased in 
U251/CP2 and T98G cells after IL-7 RNA interference (Fig. 5C 
and D). These results suggested that IL-7 could inhibit the apop-
tosis induced by cisplatin.
IL-7 mRNA expression was positively correlated with cispla-
tin resistance in glioma specimens. To determine whether IL-7 
mRNA expression was related to cisplatin resistance in clinical 
glioma samples, primary glioma specimens obtained from 91 
patients were cultured, and their IC50s for cisplatin were deter-
mined using the MTT assay. The average IC50 for cisplatin is 
2.48 ± 2.00 μg/ml. The mRNA expression of IL-7 in the cor-
responding 91 glioma specimens was detected by real time PCR. 
Pearson correlation analysis showed that the mRNA expression 
of IL-7 was positively correlated with cisplatin resistance in the 
human glioma specimens (r = 0.610, p < 0.05) (Fig. 6).
Discussion
Response to chemotherapy is often restricted by resistance 
induced by subsequent treatment. aCGH has been used to 
cisplatin-resistant cells, suggesting that these genes may not play 
a role in cisplatin resistance. The expression levels of C8orf70 
and IL-7 were higher in the U251/CP2 cells than in the U251 
cells, supporting the copy number gain in corresponding genes 
by aCGH.
Previous studies showed that autocrine production of interleu-
kins could cause multidrug resistance in cancer cells.5-7 Therefore, 
we hypothesize that IL-7 might be involved in the development 
of cisplatin resistance, and thus, we performed FISH analysis for 
IL-7 to confirm the result of aCGH. The result of the FISH anal-
ysis showed that the copy number of IL-7 was indeed amplified 
in U251/CP2 cells (Fig. 1D), which supports the aCGH analysis.
IL-7 was positively correlated with the cisplatin IC50 in 
glioma cell lines. A Spearman correlation analysis was used to 
determine the relationship between C8orf70 and IL-7 mRNA 
expression and cisplatin resistance in glioma cell lines. The 
expression levels of C8orf70 and IL-7 were detected by real time 
PCR and the IC50 for cisplatin in glioma was analyzed using 
the MTT assay (Table 3). The results showed that the C8orf70 
mRNA expression was not correlated with cisplatin resistance in 
the 12 glioma cell lines that were tested (r = -0.081, p > 0.05, 
Fig. 2B), but the IL-7 mRNA expression was positively associ-
ated with cisplatin resistance in glioma cells (r = 0.64, p < 0.05, 
Fig. 2A). This result suggested a link between IL7 overexpression 
and cisplatin resistance.
IL-7-enhanced cisplatin resistance in glioma cells. IL-7 binds 
to its receptor to mediate biological functions. To determine 
whether glioma cells have the ability to receive signaling through 
IL-7, the mRNA expression of the IL-7R was assayed in glioma 
cell lines. As shown in Figure 3A, IL-7R mRNA was expressed 
in all of the glioma cell lines that were examined, which indicated 
that the glioma cells had the ability to receive signaling through 
IL-7.
The effect of IL-7 on cisplatin resistance in glioma was fur-
ther defined by the addition of exogenous rhIL-7 and by using 
IL-7 RNA interference. Subsequent to IL-7 RNA interference 
treatment, the mRNA and protein expression levels of IL-7 were 
downregulated (Fig. 3B and C). Ten nanograms per milliliter 
or 40 ng/ml of rhIL-7 were added into medium with different 
Figure 2. The relationship between C8orf70 and IL-7 mRNA expression and the IC50 of cisplatin in glioma 
cell lines. (A) IL-7 mRNA expression is positively correlated with cisplatin resistance in glioma cell lines 
(r = 0.66, p < 0.05); (B) C8orf70 mRNA expression is not related to cisplatin resistance in glioma cell lines 
(r = -0.081, p > 0.05).© 2012 Landes Bioscience.
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analysis presented in this study has characterized four unique 
genetic aberrations, a loss of CFHR1 and CFHR3, and a gain of 
C8orf70 and IL-7 in U251/CP2 cells. This result, to our knowl-
edge, has not been reported in the literature.
Chromosome 8 open reading frame 70 (C8orf70) was located 
at chromosome 8q21.13. The amplification of chromosome 
8q21.1 is a common event in various cancers, such as prostate 
cancer, ovarian cancer and mantle cell lymphoma,15-17 however, 
there was not any evidence to indicate that chromosome 8q21.1 
was related to drug resistance. Our results showed that the expres-
sion of C8orf70 mRNA was not related to cisplatin resistance in 
glioma cell lines. The role of C8orf70 in U251/CP2 cells should 
be explored in the future.
Interleukin-7 (IL-7) is a cytokine that plays an essential role 
in the development, survival and proliferation of lymphocytes in 
screen the genomic aberrations associated with drug resistance 
in other cancers. Prasad et al.11 analyzed the genomic aberrations 
and genes in cisplatin-resistant ovarian cancer cells using high 
definition cytogenetics and oligonucleotide aCGH. Osterberg et 
al.12 explored high-resolution genomic profiling of carboplatin 
resistance in early-stage epithelial ovarian carcinoma. Hattinger 
et al.13 detected the genomic imbalances associated with metho-
trexate resistance in human osteosarcoma cell lines by compara-
tive genomic hybridization-based techniques. Struski et al.14 
identified the chromosomal loci associated with non-P-glyco-
protein-mediated multidrug resistance to the topoisomerase II 
inhibitor in a lung adenocarcinoma cell line by using comparative 
genomic hybridization. In this study, we used aCGH to deter-
mine the genomic basis of drug resistance in U251 glioma cells 
and a cisplatin-resistant subline (U251/CP2). The cytogenetic 
Figure 3. IL-7 enhanced cisplatin resistance in glioma cells. (A) The expression of IL-7 and IL-7R in glioma cell lines. (B) IL-7 mRNA expression was 
downregulated by siRNA. (C) IL-7 protein expression was downregulated by siRNA. (D) IL-7 increased the IC50 for cisplatin in U251 cells. (e) IL-7 increased 
the IC50 for cisplatin in SKMG-1 cells. (F) IL-7 interference decreased the IC50 for cisplatin in U251/CP2 cells. (G) IL-7 interference decreased the IC50 for 
cisplatin in T98G cells.© 2012 Landes Bioscience.
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cancer and breast cancer.8,19-23 IL-7 may induce the growth of 
breast cancer cells in vitro through a wortmannin-sensitive path-
way.9 Recently, it was reported that IL-7 was moderately abun-
dant in a pancreatic cancer resistant subline.24
Our aCGH study showed that IL-7 was amplified in U251/
CP2 cells, an observation that was supported by RT-PCR and 
FISH. In the present study, we determined that IL-7 can reduce 
the sensitivity of glioma cell lines to cisplatin. The IL-7 recep-
tor played a key role in the function of IL-7. IL-7R mRNA was 
expressed in all detected glioma cell lines, which indicated that 
glioma cells had the ability to accept IL-7 signaling. We hypoth-
esized that IL-7 may protect U251/CP2 cells from cisplatin by 
promoting the growth of U251/CP2 cells. It was indeed deter-
mined that IL-7 stimulated the growth of glioma cells. Our 
results have shown that IL-7 mRNA expression was associated 
with the sensitivity of glioma cell lines to cisplatin. As a growth 
factor, IL-7 not only stimulated the proliferation of lymphocyte 
cells but also induced the growth of breast cancer cells. It was 
reported that IL-7 was moderately abundant in MDR pancre-
atic cancer cells.24 Studies showed that IL-7 can inhibit apop-
tosis,10,25 and consequently, the cisplatin resistance of glioma 
cells induced by IL-7 may be related to the inhibition of apop-
tosis, which had also been confirmed 
by flow cytometry and western blot 
analysis in this study. According to 
previous studies and our results, we 
hypothesize that glioma cells produce 
and secrete IL-7, which stimulates 
their own growth and prevents apop-
tosis through IL-7R, to protect them 
from cisplatin.
In conclusion, we identified that 
the gain of IL-7 is associated with cis-
platin resistance, suggesting that IL-7 
might be a potential predictive marker 
of cisplatin resistance in glioma 
patients. Our findings may contribute 
to an increased understanding of IL-7 
overexpression in cisplatin-resistant 
glioma, and in the future, this will 
assist in designing pharmacological 
strategies for preventing, overcom-
ing or reversing cisplatin resistance in 
glioma.
Materials and Methods
Cell lines and cell culture. The 
human glioma cell lines, MGR1, 
MGR2, MGR3, SF767, SKMG-1, 
SKMG-4, T98G, U251, U373, U87 
and UWR7, were cultured in DMEM 
medium (Invitrogen-Gibco) supple-
mented with 10% fetal calf serum 
(Invitrogen-Hyclone) in a humidified 
atmosphere containing 5% CO2 at 
humans.18 Previous research showed that IL-7 can protect cells 
from death by inhibiting apoptosis via suppression of the activity 
of pro-death proteins.18 IL-7 was not only detected in leukemia 
and lymphoma but also in solid tumors, such as colon cancer, 
esophageal carcinoma, Warthin tumor, head and neck squamous 
Figure 4. IL-7 promoted the growth of glioma cells. (A) rhIL-7 promoted 
the growth of U251 and SKMG-1 cells. (B) IL-7 siRNA inhibited the 
growth of U251/CP2 and T98G cells.
Figure 5. IL-7 inhibited apoptosis induced by cisplatin in glioma cells. (A) IL-7 inhibited apoptosis 
induced by cisplatin in SKMG-1 cells. (B) IL-7 interference enhanced apoptosis induced by cisplatin in 
U251/CP2 cells. (C) IL-7 decreased the cleaved caspase-3 induced by cisplatin in U251 and SKMG-1 cells. 
(D) IL-7 interference increased the cleaved caspase-3 induced by cisplatin in U251/CP2 and T98G cells.© 2012 Landes Bioscience.
Do not distribute.
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1 min. After drying, the microarrays were scanned using a DNA 
microarray scanner G2565BA (Agilent), and the data (log2) 
were extracted from raw microarray image files using Feature 
Extraction software (version 9; Agilent). The data were analyzed 
using DNA analytics software (version 4.0; Agilent) with default 
filter settings. The aberration detection method 2 (ADM2) algo-
rithm with centralization and fuzzy zero correction was used to 
define aberrant intervals.
RNA preparation and RT-PCR. The total cell RNA was 
extracted using TRIzol reagent (Invitrogen) according to the 
manufacturer’s protocol. Reverse transcription was performed 
with 2 μg of total RNA from each sample in a total volume of 
20 μl using the RevertAid First Strand cDNA Synthesis Kit 
(Fermentas AB) according to the manufacturer’s protocol.
The sequences of the forward and reverse primers for each 
gene were listed in Table 1. Each primer was placed in a dif-
ferent exon to avoid amplification of contaminating genomic 
DNA. GAPDH was used as a loading control. Each PCR mix-
ture contained 1 μl of cDNA, 5 μl Green GoTaq DNA poly-
merase (Promega), 0.5 μl forward primer (10 μM) and 0.5 μl 
reverse primer (10 μM) in a final volume of 10 μl. PCR was per-
formed as follows: 94°C for 2 min, 30 cycles at 94°C for 30 sec, 
at annealing temperature (listed in Table 1) for 30 sec and 72°C 
for 2 min. The PCR products were separated on a 1.8% agarose 
gel, visualized by ethidium bromide staining and photographed 
with a Gel Doc XR (Bio-Rad Laboratories).
Real-time quantitative PCR was performed using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Briefly, the 
qPCR amplification was performed with 1 μl cDNA, gene-spe-
cific primers (10 μM), SYBR Premix Ex TaqTM (2x) (TaKaRa), 
ROX Reference Dye (50x) and dH2O, in a total reaction volume 
of 10 μl. After activation of Taq polymerase at 95°C for 10 sec, 
PCR was performed for 40 cycles, with each cycle consisting of 
denaturing at 95°C for 10 sec, annealing and extending at 61°C 
for 30 sec. To determine the specificity of the amplification reac-
tion, a melting curve analysis of the amplification products was 
subsequently performed. The 2-ΔΔC
T method was used to quanti-
tate gene expression.
Fluorescence in situ hybridization. IL-7 gene amplification 
was determined by FISH performed by EXONBIO CO., LTD 
(Guangzhou). Briefly, the cells were plated onto slides and fixed 
37°C. The U251/CP2 drug-resistant variant of the U251 cell line 
was established by stepwise selection after prolonged (> 10 mo) 
treatment of U251 cells with increasing concentrations of cispla-
tin (Sigma-Aldrich) in the medium. After 10 mo of culturing in 
the presence of cisplatin, the IC50 (inhibitory concentration to 
produce 50% cell death) values were 5.43 ± 0.49 μg/ml cisplatin 
for the U251/CP2 cells. To maintain the cisplatin resistance phe-
notype, cisplatin (2 μg/ml) was added to the culture medium for 
U251/CP2 cells.
Cell proliferation analysis. The cells were plated at 1,000 
cells/well in 96-well plates and incubated for an additional 24 h. 
Different concentrations of recombinant human IL-7 (rhIL-7) 
(R&D Systems) were added into wells and incubated for 72 h 
in a humidified atmosphere containing 5% CO2 at 37°C. At 
the end of the incubation, viable cells were quantified using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT). Briefly, 20 μl of the MTT stock solution (5 mg/ml) 
was added to each well of an assay. After 3 h of incubation, the 
medium was removed and the converted dye was solubilized with 
isopropanol. The absorbance of the converted dye was measured 
at a wavelength of 540 nm. The conversion to cell number was 
based on a standard curve.
Cytotoxicity analysis. The cells were plated at 2,000 cells/
well in 96-well plates and incubated for an additional 24 h. Next, 
the cells were treated with cisplatin or various concentrations of 
rhIL-7 for 72 h. The inhibition of cell-growth was evaluated at 
concentrations of 0, 0.39, 0.78, 1.5625, 3.125, 6.25, 12.5, 25 and 
50 μg/ml of cisplatin. Viable cells were quantified for 72 h after 
the administration of anticancer drugs using the MTT assay. The 
percentage of cell survival (survival rate) was calculated by divid-
ing the absorbance value of the treated sample by the absorbance 
value of the untreated control within each group. The concen-
tration of cisplatin that was required to inhibit cell growth by 
50% (IC50) was calculated from survival curves using the Bliss 
method.3
Cisplatin response testing for primary glioma specimens in 
vitro. Ninety-one fresh glioma specimens were obtained from 
surgery and were immediately submitted for cell culture and 
drug cytotoxicity testing. Briefly, glioma specimens that were 
surgically resected from patients were dissociated using collage-
nase and dispersed. The tumor cells were cultured in DMEM 
medium supplemented with 10% fetal calf serum in a humidi-
fied atmosphere containing 5% CO2 at 37°C. After culturing, 
cisplatin response testing was performed by the MTT assay as 
described in cytotoxicity analysis.
Array comparative genomic hybridization analysis (aCGH). 
aCGH was performed on the 105K CGH oligonucleotide 
microarray (Agilent Technologies) as described in reference 4. 
Briefly, 1–2 µg of sample and a sex-matched reference DNA were 
labeled, respectively, with ULS-Cy5 and ULS-Cy3 at 85°C for 
30 min (Genomic DNA ULS Labeling kit, Agilent). The puri-
fied labeled samples were mixed with human Cot-1 DNA, dena-
tured at 95°C (Oligo aCGH hybridization kit), and applied to 
microarrays. The hybridization was conducted at 65°C for 40 h. 
The microarrays were then washed in Oligo aCGH wash buffer 
1 at room temperature for 5 min and wash buffer 2 at 37°C for 
Figure 6. IL-7 mRNA expression is positively correlated with IC50 for 
cisplatin in human glioma specimens.© 2012 Landes Bioscience.
Do not distribute.
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Z2) equipped with a single green, orange and triple band pass 
filter Dapi-FITC-Cy3.
siRNA transfection. For transfection, cells were plated in six-
well plates (2 × 105 cells per well) and were allowed to adhere for 
24 h. IL-7 siRNA or Negative Control siRNA (Table 2) were 
synthesized by Shanghai GenePharma Co., Ltd., and trans-
fected into U251/CP2 and T98G cells using lipofectamine 2000 
(Invitrogen), with the siRNA at a final concentration of 200 nM 
according to the manufacturer’s instructions. The cells were ana-
lyzed 72 h after transfection.
Western blot analysis. A mouse anti-IL7 monoclonal anti-
body was obtained from Abcam (Cambridge). Anti-GAPDH as 
well as anti-caspase-3 antibodies were obtained from Santa Cruz 
Biotech. For western blot analysis, the cells were washed with 
ice-cold PBS after treatment and lysed on ice using RIPA. After 
centrifugation at 13,000x g for 5 min, the protein concentration 
of the supernatant was analyzed using a BCA assay kit. For the 
analysis of protein contents, 40 μg of total protein was electropho-
resed on a 10% SDS-PAGE gel, transferred to PVDF membranes 
and the membranes were then incubated with the respective 
antibodies indicated above. Membranes were developed with a 
chemiluminescent reagent (Pierce Chemical Co.) and the bands 
were exposed to Biomax MR film (Eastman Kodak).
Apoptosis assay. Apoptosis was assayed using the Annexin 
V-FITC Apoptosis Kit (Keygen Biotech Co., Ltd.) according to 
the manufacturer’s instructions. Briefly, the cells were harvested 
and washed twice with PBS. Next, each sample was centrifuged 
at 1,000x g for 5 min and suspended again in 500 μl of binding 
buffer. Five microliters of Annexin V-FITC and 5 μl of prop-
idium iodide (PI) working solutions were added. The samples 
were then analyzed by flow cytometry (FCM).
Statistical analysis. Each experiment was repeated at least 
three times. Numerical data were presented as the mean ± SD. 
The difference between means was analyzed using Student’s 
t-test. The correlations were determined with bivariate correla-
tion procedures (Spearman correlation coefficient, p < 0.05). All 
statistical analyses were performed using SPSS17.0 for Windows 
(SPSS). The differences were considered significant when p < 
0.05.
by 4% paraformaldehyde at 50–70% confluence. The sections 
were pretreated in PBS for 20 min followed by protease diges-
tion at 37°C for 26 min. An appropriate amount of hybridiza-
tion solution containing directly labeled probes was applied, and 
the probe-target cells were codenatured for 5 min at 72°C using 
Hybridizer (DAKO Diagnostics) and allowed to hybridize for 19 
h at 37°C. Non-hybridized probe was washed out in 72°C 2x 
SSC with 0.3% NP-40 solution for 2 min. Nuclei were counter-
stained with DAPI, covered with a glass coverslip and stored at 
-20°C until analyzed. Hybridized probes were examined manu-
ally using a fluorescence Zeiss microscope (Zeiss, Axio Imager.
Table 1. PCR primer sequences
Name Oligonucleotide Sequence (5–3) Size (bp) Tm
CFHR1 Forward GTT ATG AAT GTA GGA GCC CTT ATG 158 55
Reverse TGA CAA CGG GAA TGA AGT AAT G
CFHR3 Forward TGT GGG TTT CCT GTG CTA ATG 375 55
Reverse GAG ACC AGC CTT TCT CCG TA
C8orf70 Forward GAT GGA GGG ACT GGA AGA G 353 53
Reverse CAG GAT CAT AAG AAG GTG GAG
IL-7 Forward GAG TGA CTA TGG GCG GTG AGA G 146 61
Reverse GAT GCT ACT GGC AAC AGA ACA AGG
IL-7R Forward ATG CCT GGC TGG GAA TGT C 197 53
Reverse CCT GAG CAA CTG GGT TCA ATG
GAPDH Forward CGC TCT CTG CTC CTC CTG TTC 108 61
Reverse ATC CGT TGA CTC CGA CCT TCA C
Table 2. siRNA sequences
Name Sequence (5–3)
IL-7 siRNA Sense 5' GCA UCA UCU GAU UGU GAU ATT 3'
IL-7 siRNA Anti-Sense 5' UAU UCA GGC AAU UGC UAC CTT 3'
Negative Control Sense 5' UUC UCC GAA CGU GUC ACG UTT 3'
Negative Control Sense 5' ACG UGA CAC GUU CGG AGA ATT 3'
Table 3. IC50 for cisplatin in glioma
Cell line IC50 for cisplatin (μg/ml)
MGR1 2.59 ± 0.22
MGR2 2.46 ± 0.19
MGR3 4.83 ± 0.36
SF767 0.57 ± 0.13
SKMG-1 1.29 ± 0.13
SKMG-4 1.14 ± 0.16
T98G 3.8 ± 0.33
U251 1.12 ± 0.12
U373 1.74 ± 0.16
U87 1.73 ± 0.19
UWR7 1.69 ± 0.11
SF295 1.07 ± 0.12© 2012 Landes Bioscience.
Do not distribute.
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Table 4. IC50 for cisplatin in glioma following IL-7 or siRNA treatment
Cell line Treatment IC50 for cisplatin (μg/ml)
U251
control 1.12 ± 0.21
10 ng/ml IL-7 2.1 ± 0.21
40 ng/ml IL-7 3.18 ± 0.25
SKMG-1
control 1.18 ± 0.13
10 ng/ml IL-7 1.96 ± 0.16
40 ng/ml IL-7 2.73 ± 0.23
U251/CP2
control 5.05 ± 0.36
siRNA 2.53 ± 0.26
T98G
control 3.52 ± 0.28
siRNA 1.74 ± 0.14
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